January 24, 2023
AmerisourceBergen Kicks Off Strategic Relationship with Civica
AmerisourceBergen will serve as Civica, Inc.โs exclusive distribution partner, providing supply chain support for Civicaโs products and working to ensure that Civicaโs crucial products reach its members across the country efficiently, reliably and securely. The partnership aims to accelerate mutual efforts to ensure the stability of supply of essential generic medicines nationwide.
Media Coverage
January 31, 2023
Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative
“As a renowned injection device specialist with over 35 yearsโ experience, Ypsomed will help Civica make self-administered care more affordable for Americans living with diabetes,โ said Ned McCoy, President and Chief Executive Officer of Civica. โCivica will deliver affordable, high-quality insulin, in the best pen platform, utilizing our new, state of the art manufacturing technology in Petersburg, Virginia.”
Media Coverage
February 8, 2023
Utah-based Nonprofit Set to Open $140M Insulin Plant in Petersburg
Petersburg is at the center of a nonprofitโs push to lower sky-high insulin costs. Utah-based Civica Rx is in the final stages of building a $140 million insulin production plant in the city.
Media Coverage
March 18, 2023
California Selects Civica Rx as Its Insulin Manufacturing Partner
Californiaโs partnership with Civica is a game changer,โ said California Governor Gavin Newsom, announcing the stateโs choice of Civica to manufacture insulins for the State of Californiaโs CalRx Biosimilar Insulin Initiative. โWe are proud to be working with Civica to bring true price competition into the insulin drug market and ease the financial burden for Californians living with diabetes.”
Media Coverage
April 11, 2023
CivicaScript, SortPak Partner to Package & Deliver Medicines to Maximize Patient Convenience, Compliance & Savings
CivicaScript, which is dedicated to bringing lower-cost generic medicines to U.S. consumers, and SortPak, which delivers pre-sorted medications to patients at no extra cost to patients or health plans, are partnering to provide CivicaScript medicines in packaging designed to maximize patient convenience, savings and medication compliance.
Media Coverage
April 20, 2023
What Spurred Lilly, Novo and Sanofi to Slash Insulin Prices? Expert Gives Her Take
The price cuts can be explained by a mix of factors, Leemore Dafny, Ph.D., wrote in a new analysis for The New England Journal of Medicine, titled โFalling Insulin Prices โ What Just Happened?โ One: The market is awaiting the entry of certain manufacturers that โdonโt benefit from high prices.โ Two: Government regulations are making it โcostlierโ for insulin manufacturers to keep charging their prior prices. Three: Public shaming.
Media Coverage
May 3, 2023
CivicaRx Disrupts Out of Control Prescription Medication Pricing
Civica believes its model of rallying others to work together to ensure a reliable supply of fairly priced medicines is one that the wider pharmaceutical industry can ultimately support.
Media Coverage
June 13, 2023
Jay Benson Joins Civica Rx as Chief Manufacturing and Supply Chain Officer
Biopharma industry veteran Jay Benson has joined Civica as Chief Manufacturing and Supply Chain Officer, replacing Russ Gall who recently announced his retirement.
Media Coverage
July 27, 2023
Lawmakers Seek to Boost Domestic Manufacturing, Taking Action on Critical Drug Shortages
A new bill, the RAPID Reserve Act, would require the Department of Health and Human Services to dole out $500 million in awards for generic drug manufacturing to either US-based companies or member countries of the Organization for Economic Co-operation and Development.
Civica President and CEO Ned McCoy welcomed the bill, saying, โThe focus on creating additional safety stock inventory within the supply chain and on upgrading aging generic drug manufacturing infrastructureโฆhave the potential to significantly reduce shortages.โ
September 5, 2023
Disrupting Drug Market Prices and Supply
Civica Rx Board Chair Dan Liljenquist describes the nonprofit generic pharmaceutical companyโs mission, structure and influences on the market, saying, โWhen market failures are hurting people, new markets should emerge to correct that failure.โ
September 6, 2023
Civica Celebrates 5th Anniversary
Today, we celebrate Civicaโs 5th Anniversary! Five years of building our talented team and lasting partnerships with likeminded organizations. Five years of delivering on and expanding our mission to make quality generic medications available and affordable to everyone. And, five years of doing what is in the best interest of patients.
We thank the Civica team for all they do to put patients first; our members and partners for their dedication to our shared mission; and the generous donors who are helping to make affordable insulin a reality. We are deeply appreciative and look forward to continuing our work together. Our mission is as important as ever!
Watch this video to see how far weโve come and whatโs next!
November 1, 2023
Bouwien Smits Joins Civica Rx as Site Vice President and General Manager of New Virginia Manufacturing Facility
Industry veteran Bouwien Smits will run state-of-the-art production of low-cost insulin as well as dozens of other medicines.
Media Coverage
November 7, 2023
Civica Rx Named a Best Place to Work
Civica has been named a Best Place to Work by BioSpace, recognized in part for its emphasis on culture and innovation.
Media Coverage
December 6, 2023
Civica Testifies on Drug Shortages before the U.S. Senate Finance Committee
Civica was invited to provide insights on drug shortages during a Congressional hearing. In his testimony before the U. S. Senate Committee on Finance, Civicaโs Senior Vice President of Public Policy Allan Coukell said, “Make no mistake: Drug shortages are not a passing storm that will soon blow over. After a dozen years, shortages must now be understood as a built-in and permanent outcome of our current system.”
Hear Allanโs opening testimony and view the full hearing (Drug Shortages: Examining Supply Challenges, Impacts, and Policy Solutions from a Federal Health Program Perspective).